Inhibition of hypoxia-induced epithelial mesenchymal transition by luteolin in non-small cell lung cancer cells

Molecular Medicine Reports

Volumn 6, Issue 1, 2012, Pages 232-238

  Ruan, Junshan ^a,b   Zhang, Lei ^a   Yan, Linggeng ^a   Liu, Yuping ^a   Yue, Zhiqiang ^a   Chen, Li ^a   Wang, Ai Yun ^a   Chen, Wenxing ^a   Zheng, Shizhong ^a   Wang, Shaoming ^b   Lu, Yin ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Focal adhesion kinase; Hypoxia; Integrin 1; Lung cancer; Luteolin

Indexed keywords

BETA1 INTEGRIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; LUTEOLIN; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL ASSAY; CELL MOTILITY; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HYPOXIA; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; METASTASIS; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRIN BETA CHAINS; LUNG NEOPLASMS; LUTEOLIN; SIGNAL TRANSDUCTION;

EID: 84861603289     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.884     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Cataldo VD, Gibbons DL, Perez-Soler R and Quintas-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364: 947-955, 2011.
3. Grimminger F, Schermuly RT and Ghofrani HA: Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 9: 956-970, 2010.
4. Kuner R, Muley T, Meister M, et al: Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer 63: 32-38, 2009.
5. Le QT and Courter D: Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev 27: 351-362, 2008.
6. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS and Wu KJ: Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 64: 1082-1089, 2009.
7. Pine SR, Ryan BM, Varticovski L, Robles AI and Harris CC: Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci USA 107: 2195-2200, 2010.
8. Kim WY, Perera S, Zhou B, et al: HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119: 2160-2170, 2009.
9. Chowdhury AR, Sharma S, Mandal S, Goswami A, Mukhopadhyay S and Majumder HK: Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J 366: 653-661, 2002. (Pubitemid 35001710)
10. Hirano T, Higa S, Arimitsu J, et al: Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochem Biophys Res Commun 340: 1-7, 2006. (Pubitemid 41827640)
11. Ueda H, Yamazaki C and Yamazaki M: Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull 25: 1197-1202, 2002. (Pubitemid 39655163)
12. Attoub S, Hassan AH, Vanhoecke B, et al: Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol 651: 18-25, 2011.
13. Amin AR, Wang D, Zhang H, et al: Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem 285: 34557-34565, 2010.
14. Lin YS, Tsai PH, Kandaswami CC, et al: Effects of dietary flavonoids, luteolin, and quercetin on the reversal of epithelial-mesenchymal transition in A431 epidermal cancer cells. Cancer Sci 102: 1829-1839, 2011.
15. Bagli E, Stefaniotou M, Morbidelli L, et al: Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res 64: 7936-7946, 2004. (Pubitemid 39446927)
16. Lin Y, Shi R, Wang X and Shen HM: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8: 634-646, 2008.
17. Gupta R, Chetty C, Bhoopathi P, et al: Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol 38: 733-744, 2011.
18. Johnson FM, Saigal B, Talpaz M and Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932, 2005. (Pubitemid 41428750)
19. Shah PP, Fong MY and Kakar SS: PTTG induces EMT through integrin alpha(V)beta(3)-focal adhesion kinase signaling in lung cancer cells. Oncogene: Nov 14, 2011 (Epub ahead of print).
20. Blanco E, Bey EA, Khemtong C, et al: Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res 70: 3896-3904, 2010.
21. Tauler J, Zudaire E, Liu H, Shih J and Mulshine JL: hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res 70: 7137-7147, 2010.
22. Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33, 2009
23. Thomson S, Buck E, Petti F, et al: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-9462, 2005. (Pubitemid 41508014)
24. Yauch RL, Januario T, Eberhard DA, et al: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698, 2005. (Pubitemid 43005918)
25. Leung HW, Hour MJ, Chang WT, et al: P38-associated pathway involvement in apoptosis induced by photodynamic therapy with Lonicera japonica in human lung squamous carcinoma CH27 cells. Food Chem Toxicol 46: 3389-3400, 2008.
26. You BJ, Wu YC, Bao BY, et al: Rottlerin inhibits Lonicera Japonica-induced photokilling in human lung cancer cells through cytoskeleton-related signaling cascade. Evid Based Complement Alternat Med 2011: 193842, 2011.
27. Lee HZ, Bau DT, Kuo CL, Tsai RY, Chen YC and Chang YH: Clarification of the phenotypic characteristics and anti-tumor activity of Hedyotis diffusa. Am J Chin Med 39: 201-213, 2011.